ScholarIQanswers from OpenAlex & ORCID
Fumio Imamura
ResearcherPublications, citations & collaboration network
Fumio Imamura is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Fumio Imamura have?
ScholarIQindexed works
Fumio Imamura has 399 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Fumio Imamura have?
ScholarIQcitation count
Fumio Imamura has 23,512 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Fumio Imamura?
ScholarIQh-index
Fumio Imamura has an h-index of 56 in OpenAlex.
What is the i10-index of Fumio Imamura?
ScholarIQi10-index
Fumio Imamura has an i10-index of 140 in OpenAlex.
What is the ORCID of Fumio Imamura?
ScholarIQorcid
The ORCID for Fumio Imamura is on the source record.
What is the OpenAlex record for Fumio Imamura?
ScholarIQopenalex
The OpenAlex for Fumio Imamura is on the source record.
What are the most-cited papers on Fumio Imamura?
ScholarIQmost cited works
Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer
Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata, Isamu Okamoto, Caicun Zhou, Byoung Chul Cho, Ying Cheng, Eun Kyung Cho, Pei Jye Voon, David Planchard, Wu‐Chou Su, Jhanelle E. Gray, Siow Ming Lee, Rachel Hodge, Marcelo Marotti, Yuri Rukazenkov, Suresh S. Ramalingam
Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC
Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard, Byoung Chul Cho, Jhanelle E. Gray, Yuichiro Ohe, Caicun Zhou, Thanyanan Reungwetwattana, Ying Cheng, Busyamas Chewaskulyong, Riyaz Shah, Manuel Cobo, Ki Hyeong Lee, Parneet Cheema, Marcello Tiseo, Thomas John, Meng‐Chih Lin, Fumio Imamura, Takayasu Kurata, Alexander Todd, Rachel Hodge, Matilde Saggese, Yuri Rukazenkov, Jean‐Charles Soria
Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo, Young Hak Kim, Koichi Azuma, Takashi Seto, Yuichi Takiguchi, Makoto Nishio, Hiroshige Yoshioka, Fumio Imamura, Katsuyuki Hotta, Satoshi Watanabe, Kōichi Goto, Miyako Satouchi, Toshiyuki Kozuki, Takehito Shukuya, Kazuhiko Nakagawa, Tetsuya Mitsudomi, Nobuyuki Yamamoto, T. Asakawa, Ryoichi Asabe, Tomohiro Tanaka, Tomohide Tamura
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto, Makoto Nishio, Santiago Ponce Aix, Luis Paz‐Ares, Chao‐Hua Chiu, Keunchil Park, Silvia Novello, Ernest Nadal, Fumio Imamura, Kiyotaka Yoh, Jin‐Yuan Shih, Kwok Hung Au, Denis Moro‐Sibilot, Sotaro Enatsu, Annamaria H. Zimmermann, Bente Frimodt‐Moller, Carla Visseren‐Grul, Martin Reck, Quincy S. Chu, Alexis B. Cortot, Jean-Louis Pujol, Denis Moro‐Sibilot, Elizabeth Fabre, Corinne Lamour, Helge Bischoff, Jens Kollmeier, Martin Reck, Martin Kimmich, Walburga Engel-Riedel, Stefan Hammerschmidt, Wolfgang Schütte, Konstantinos Syrigos, Jcm Ho, Kwok‐Hung Au, Silvia Novello, Andrea Ardizzoni, Giulia Pasello, Vanessa Gregorc, Alessandro Del Conte, Domenico Galetta, Toshiaki Takahashi, Kazuhiko Nakagawa, Makoto Nishio, Kiyotaka Yoh, Takashi Seto, Fumio Imamura, Toru Kumagai, Katsuyuki Hotta, Yasushi Goto, Yukio Hosomi, Hiroshi Sakai, Yuichi Takiguchi, Young Hak Kim, Takayasu Kurata, Hiroyuki Yamaguchi, Haruko Daga, Isamu Okamoto, Miyako Satouchi, Satoshi Ikeda, Kazuo Kasahara, Shinji Atagi, Koichi Azuma, Toru Kumagai, Keisuke Aoe, Toru Kumagai, Keisuke Aoe, Yoshitsugu Horio, Nobuyuki Yamamoto, Hiroshi Tanaka, Satoshi Watanabe, Naoyuki Nogami, Tomohiro Ozaki, Ryo Koyama, Tomonori Hirashima, Hiroyasu Kaneda, Keisuke Tomii, Yuka Fujita, Masahiro Seike, Naoki Nishimura, Terufumi Kato, Masao Ichiki, Hideo Saka, Katsuya Hirano, Yasuharu Nakahara, Shunichi Sugawara, Keunchil Park, Sang‐We Kim, Young Joo Min, Hyun Woo Lee, Jin‐Hyoung Kang, Ho Jung An, Ki Hyeong Lee, Jin-Soo Kim, Gyeong‐Won Lee, Sung Yong Lee, Aurelia Alexandru, Anghel Adrian Udrea, Óscar Juan
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim, Julien Mazières, Johan Vansteenkiste, H. Léna, Jesus Corral Jaime, Jhanelle E Gray, John D. Powderly, C. Chouaïd, Paolo Bidoli, Paul Wheatley‐Price, Keunchil Park, Ross A. Soo, Yifan Huang, Catherine Wadsworth, Phillip A. Dennis, Naiyer A. Rizvi, Luis Paz-Ares Rodríguez, Silvia Novello, Sandrine Hiret, Peter Schmid, Eckart Laack, Raffaele Califano, Makoto Maemondo, Sang‐We Kim, Jamie E. Chaft, David Vicente Baz, Thierry Berghmans, Dong‐Wan Kim, Veerle Surmont, Martin Reck, Ji‐Youn Han, Esther Holgado Martin, Cristóbal Belda-Iniesta, Yuichiro Oe, Antonio Chella, Akhil Chopra, G. Robinet, Héctor Soto Parrà, Michael J. Thomas, Parneet Cheema, Nobuyuki Katakami, Wu‐Chou Su, Young‐Chul Kim, Juergen Wolf, Jong-Seok Lee, Hideo Saka, Michele Stanislaw Milella, Inmaculada Ramos García, Anne Sibille, Takashi Yokoi, Eun Joo Kang, Shinji Atagi, E. Spaeth-Schwalbe, Makoto Nishio, Fumio Imamura, Nashat Gabrail, Rémi Veillon, Sofie Derijcke, Tadashi Maeda, Dylan M. Zylla, Kendra Kubiak, Armando Santoro, Ma. Noemi Uy, Sarayut Lucien Geater, Antoîne Italiano, Dariusz M. Kowalski, Fabrice Barlési, Yuh‐Min Chen, David R. Spigel, Busyamas Chewaskulyong, Ramón García Gómez, Rosa Álvarez, Chih-Hsin Yang, Te‐Chun Hsia, Fabrice Denis, Hiroshi Sakai, Mark Vincent, Kōichi Goto, Joaquim Bosch‐Barrera, Glen J. Weiss, Jean-Luc Canon, Christian W. Scholz, Massimo Aglietta, Hirotsugu Kemmotsu, Koichi Azuma, Penelope A. Bradbury, Ronald Feld, Abraham Chachoua, Jacek Jassem, Rosalyn A. Juergens, Ramon Palmero Sanchez, Albert Malcolm, Nandagopal Vrindavanam, Kaoru Kubota, Cornelius F. Waller, David Waterhouse, Bruno Coudert, Z. Mark